Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

• Published in: Alimentary pharmacology & therapeutics Vol. 53; no. 2; pp. 314 - 320
• Main Authors: Brakenhoff, Sylvia M., Man, Robert A., Boonstra, André, Campenhout, Margo J. H., Knegt, Robert J., Bömmel, Florian, Eijk, Annemiek A., Berg, Thomas, Hansen, Bettina E., Janssen, Harry L. A., Sonneveld, Milan J.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.01.2021; John Wiley and Sons Inc
• Subjects: Antigens; Antigens, Viral - therapeutic use; Antiviral Agents - therapeutic use; Clinical trials; DNA, Viral; Hepatitis B; Hepatitis B e antigen; Hepatitis B e Antigens; Hepatitis B surface antigen; Hepatitis B Surface Antigens; Hepatitis B virus - genetics; Hepatitis B, Chronic - drug therapy; Humans; Interferon; Original; Predicting Sustained Response in Hepatitis B; Probability; Randomized Controlled Trials as Topic; Ribonucleic acid; RNA; RNA - therapeutic use; RNA viruses; Treatment Outcome

Summary Background Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti‐viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off‐treatment response is yet unclear. Aim To study the degree...